Health innovations with impact
We invest entrepreneurially in MedTech and digital health – for measurable progress in care and strong, scalable companies.
What we do
OYNOVA is a holding and investment company with a clear focus on medical technology and digital health solutions. We prefer to invest in companies with demonstrable clinical relevance, robust evidence and scalable business models that create real added value in patient care.
Our approach combines strategic capital with decades of experience in commercialisation, market access and international expansion. We open up networks of strategic partners to accelerate growth and lasting impact.
OYNOVA invests for the long term and with an entrepreneurial mindset. We work closely with founding teams, develop robust growth strategies and establish transparent KPI management. Our contribution is pragmatic and results-oriented: better patient care, more efficient processes and sustainable revenue paths.
Vision, mission & positioning
Vision
A future in which technological innovation redefines access to better health worldwide: safe, scalable and economically viable.
Mission
We invest in companies that noticeably improve people's health through medical technology and digital health. We act for the long term, entrepreneurially and in partnership, and create value through capital, execution experience and strategic support.
Positioning
OYNOVA is the entrepreneurial investment platform for high-impact innovations in MedTech and digital health, focused on rapid scaling, robust evidence and clear economic results.
Our goal is measurable, lasting impact in patient care and across the entire healthcare system. We combine clinical benefit with economic viability and create value that benefits both patients and the healthcare system.
About us - philosophy & principles
Who we are
OYNOVA is a GmbH with a clear investment focus on human health. We manage our own assets, acquire and hold investments strategically, and support portfolio companies with hands-on growth support on their way to market leadership.
Our founder and investment team combine decades of experience in commercialisation, market access, clinical adoption and international scaling. This concentrated expertise makes us the ideal partner for ambitious MedTech and digital health companies.
How we think
Impact before volume. Evidence before hype.
We invest where clinical benefit, economic viability and excellence in execution come together and where our contribution accelerates the next stage of growth. Our investment decisions are based on hard facts, robust data and demonstrable relevance to care.
Investment focus & strategy
Medical technology
Therapy, intervention, diagnostics, robotics and wearables with demonstrable clinical benefit and regulatory maturity
Digital health
Software as a medical device, clinical decision support, remote monitoring, workflows, data platforms and AI-based applications with a clear evidence pathway
Stages
Late seed to growth (Series A–C)
Prerequisite: initial clinical or commercial proof, a clear path to reimbursement or robust cash flows in self-pay or B2B models.
Geography
Europe with an EMEA focus
Selectively global where strategic fit, regulatory clarity and scaling potential are given.
Types of investment
Flexible & strategic
Minority stakes with active support, co-investments with strategic partners.
Our selection criteria
Our goal is measurable, lasting impact in patient care and across the entire healthcare system. We combine clinical benefit with economic viability and create value that benefits both patients and the healthcare system.
Clinical benefit
Clear medical relevance, addressed indications with significant patient benefit, convincing safety and efficacy data or a robust evidence pathway with documented clinical outcomes.
Market access
A demonstrable path to reimbursement (DRG/OPS, supplementary payments, national HTA routes) or a robust, proven business model without reimbursement dependency, backed by reliable willingness-to-pay data.
Team & governance
An experienced core team with proven execution strength, a visible learning curve from previous scaling phases, robust governance structures and a professional reporting system.
Regulatory & quality
MDR/FDA status transparently documented, QMS maturity demonstrable, software classification clearly defined for digital health, roadmap to further approvals plausible and resourced.
Commercial scalability
Repeatable sales, scalable unit economics, a coherent go-to-market logic (direct, hybrid, distributor), a transparent pipeline structure and reliable forecasts.
Data & digitalisation
A well-thought-out data strategy, interoperability ensured, state-of-the-art IT security, a comprehensive data protection concept; for AI products: validation, bias mitigation and auditability fully documented.
Our added value – value creation playbook
Beyond capital, we provide hands-on support in all growth-critical areas of the investment case. Our expertise accelerates market access, optimises commercial excellence and establishes measurable performance systems.
Market access & reimbursement
Roadmaps per market, supplementary payments and funding levers, dossier logic, pricing and reimbursement strategy, early budget-impact argumentation, HTA preparation
Go-to-market EMEA
Phased plan for tier 1/2 markets, systematic reference building, training and proctoring programmes, clinical adoption strategy, post-market evidence, medical education
Organisation & governance
OKR/KPI systems, PMO support in growth phases, sales and marketing cadence, forecast and BI dashboards for data-driven decisions
Commercial excellence
Segmentation, ideal customer profiles, account prioritisation, building reference centres, KOL network, funnel KPIs, revenue forecasts, pricing logic, distributor management
Evidence & real-world data
Study support, registry design, RWD/RWE concepts, health economic models, publication and congress strategy for maximum scientific visibility
Digital health specifics
Approval/CE classes, interoperability, hospital IT integration, security/privacy by design, clinical evaluation of software products, reimbursement routes (selective contracts, hospital licences)
Impact & measurability
We measure success not only in euros, but in demonstrable improvements in patient care and efficiency gains in the healthcare system. Our impact framework documents measurable progress across several dimensions.
- Clinical metrics
Time to therapy, complication rates, re-interventions, patient-reported outcomes, quality-of-life improvements
- Economic metrics
Cost per case, length of stay, resource use, budget impact, total cost savings in the system
- Adoption metrics
Number of active centres, intensity of use, repurchase rates, net retention, referral quality
- Market access metrics
Reimbursement status per country, positive HTA assessments, supplementary payments, selective contracts, reimbursement rates
- Compliance & quality
Audit results, vigilance performance, MDR conformity, post-market surveillance quality
